UPClytics
View all cases

UPC APP 16366/2025

·EP4183412: RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME

Case details
Status
Action
Procedural application
Category
Withdrawal Applications
Division
Milan CD
Judges
Technology
Biotechnology
Language
First decided
Apr 22, 2025
Decisions
  • 2025-04-22
    WithdrawnApplication Rop 265

    Milan Central Division procedural order granting Pfizer's application to withdraw a revocation action against GlaxoSmithKline Biologicals SA concerning EP 4 183 412 (RSV F protein vaccine patent), and a separately filed counterclaim for revocation in parallel Düsseldorf infringement proceedings (which had been referred to the Central Division). Pfizer and Glaxo had each filed applications to amend the patent; both revocation actions were withdrawn by Pfizer prior to closure of the written procedure. The court also ordered 60% reimbursement of court fees and confirmed each party bears its own costs.

    Legal issues:Withdrawal of revocation action (R. 265.1 RoP)Reimbursement of court fees (R. 370 RoP)Referral of counterclaim for revocation from local to central divisionApplication to amend patent
Documents
  • 83A40873F1721B10D2423F4CB5182319_en.pdf2025-04-22EN
Pfizer, Inc. v GlaxoSmithKline Biologicals SA — UPC APP 16366/2025 | UPClytics